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INTRODUCTION
The complement cascade is an ancient part of our innate immune system that can be activated following tissue injury/damage and in response to foreign bodies 1 . Following activation of the cascade the complement peptides C3a, C4a and C5a are generated prior to the termination of the cascade with the formation of the membrane attack complex 1 . C5a is a potent immunomodulator, but also has emerging roles outside of immunity during embryonic development 23 . Its production is tightly controlled in order to produce a rapid response to tissue injury/pathogens yet protect against unwanted activity on host tissue 1, 4 . The disruption of this control can lead to the overproduction of C5a, which can lead to an uncontrolled inflammatory response. C5a has been associated with a number of autoimmune, inflammatory and neurodegenerative disorders 5, 6 although, interestingly, the overproduction of C5a can lead to a down regulation of the immune response in some leukocytes, but have the opposite effect on other cell types 7 .
Two receptors have been shown to bind C5a: the C5a receptor 1 (C5aR1 or CD88) and the C5a receptor 2 (C5aR2 or C5L2) 8, 9 . C5aR1 and C5aR2 are known to have important functions in many inflammatory conditions 4 . C5aR1 is a classical G protein-coupled receptor (GPCR) and activation following C5a binding leads to predominantly Gα i activation which in turn activates multiple intracellular signalling pathways (including ERK, Akt, MAPK and PI3K) and β-arrestin recruitment for receptor desensitisation, recycling and perhaps also Gprotein independent signalling 1, 4 . C5aR2 is a seven transmembrane domain receptor but is not coupled to G-proteins, partly due to key amino acid changes in the critical cytosolic DRY and NPXXY motifs where G-proteins have been shown to bind 10 . However, C5aR2 has been shown to bind to β-arrestins 11, 12 . C5aR2 was originally thought to be a simple recycling decoy receptor, similar to the chemokine receptor D6 13 . This assumption is no longer accepted as C5aR2 has now been shown to have both pro-and anti-inflammatory activities, and also to have its own functional role, which is likely to be regulated through β-arrestin recruitment and signalling 14, 15 . We have recently published a model that potentially explains the contradictory 4 role of C5aR2 having both pro-and anti-inflammatory activities, through the modulation of C5a induced C5aR1 signalling via C5aR2 mediated β−arrestin recruitment 16 .
Discovery of functionally selective C5aR2 ligands
One inflammatory condition that is strongly associated with the dysregulation of C5a is septicaemia 7 . The detrimental effects of C5a in sepsis have been well studied and include paralysis of neutrophil immune function, promotion of septic cardiomyopathy, driving the apoptosis of adrenal medullar cells and thymocytes, and consumptive coagulopathy which can all lead to multi-organ failure 5 . Using the caecal ligation and puncture (CLP) model of high grade sepsis in mice it was shown that C5aR1 and C5aR2 null animals had an 85% and 80% survival rate, respectively at day 3 compared to 0% in normal mice 17 . This data suggests that there is a cooperative interaction between C5aR1 and C5aR2 during the development of sepsis and that blocking of C5a, or both its receptors, could be a very effective therapeutic treatment option 18 . The pro-inflammatory cytokine IL-6 has been shown to play a key role in septicaemia and is involved in regulating the expression of C5aR1 during septicaemia 19 .
The physiological role of C5aR2 however under both pathological and normal conditions remains controversial, but it is apparent that it has an important role in C5a biology and inflammatory disease 20 . A major issue for the field has been lack of selective ligands for C5aR2, as current ligands either target C5aR1 alone or interact with both receptors. As such, all of the information generated on C5aR2-specific activity to date has been obtained using C5aR2 -/-mice, C5aR2 genetic knockdown, or C5aR2 blocking antibodies, which each come with their own limitations. In order to better understand the contribution of C5aR2 to C5a biology, selective ligands for this receptor are required.
Recently, we designed a library of small peptides based on the C-terminus of C5a
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Surprisingly, none of these peptides induced or inhibited C5aR1 activity, but several were instead selective C3aR agonists, giving evidence for the promiscuity of ligands designed to target the complement activation peptide receptors. In the current study we further interrogated this library for activity at C5aR2 using a radioligand assay to assess binding to C5aR2 expressing membranes, followed by a bioluminescence resonance energy transfer (BRET) assay
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5 to measure β-arrestin 2 recruitment. Two partial agonists were identified that could recruit β-arrestin 2, selectively inhibit the release of IL-6 and modulate C5a-induced ERK1/2 activation in human monocyte-derived macrophages (HMDMs), and inhibit C5a-induced neutrophil mobilization in vivo in a C5aR2 dependent manner. Here we describe the first functionally selective C5aR2 ligands, which can recruit β-arrestin 2, selectively inhibit the release of IL-6
and modulate C5a-induced ERK1/2 activation in HMDMs, and inhibit C5a-induced neutrophil mobilization in vivo in a C5aR2-dependent manner.
RESULTS

Binding of complement proteins to C5aR2
We initially utilised a Flp-In CHO-C5aR2 membrane preparation to test for the binding activity of the anaphylatoxins at C5aR2 using an 125 I-C5a displacement scintillation proximity assay (SPA). There is still some controversy in the literature as to whether C5aR2 is the receptor for C3a-des Arg/acylation-stimulating protein (ASP), with more recent data in the literature that suggests this is not the case
22
. In our studies, neither C3a nor C3a-des Arg (at concentrations up to 1 µM) showed any discernible displacement of 125 I-C5a from Flp-In CHO-C5aR2 membrane preparations, whilst both C5a and C5a-des Arg displayed full and potent inhibition (Fig. 1 ).
This further confirms that C3a and C3a-des Arg (ASP) do not bind to human C5aR2 as has been previously reported 23 . Furthermore, C5a-des Arg was originally described as a ligand for C5aR2 but our data here are in agreement with recent data showing that C5a-des Arg has similar affinity/potency as C5a for both C5aR1 and C5aR2 16, 24 . This suggests that the functional roles of C5a and C5a-des Arg are very similar at C5aR2, and the description of C5a-des Arg as a predominant ligand for C5aR2 over C5aR1 can no longer be supported.
Screening peptide library for binding to C5aR2 and counter screening hits against C5aR1
Initially the library was screened at a single concentration of 100 µM for inhibition of C5aR2 membranes when compared to buffer control ( Fig. 2A) Due to the non G-protein signalling nature of C5aR2, a BRET C5aR2-β-arrestin 2 recruitment assay, previously developed in our lab 16 , was used to test peptides for functional activity at C5aR2. Both, P32 and P59 were identified as partial agonists for the recruitment of β-arrestin 2 via C5aR2 (Table 1) . Neither ligand could recruit β-arrestin 2 to the same level as C5a, but they could recruit β-arrestin 2 at a similar rate to C5a (Fig. 3A) . P32 and P59 dose dependently recruited β-arrestin 2 via C5aR2 with significantly higher efficacy than their binding affinity for C5aR2 (Fig. 3B , . Neither, P32 or P59 could recruit β-arrestin 2 via C5aR1 (Fig. 3C) , giving further evidence for the selectivity of the ligands for C5aR2. In addition, the complete library was tested for ligand induced β-arrestin 2 recruitment at C5aR1 and C5aR2 using DiscoverX
PathHunter kits. Only P32 and P59 showed activity at C5aR2 and no peptide had any activity at C5aR1 (data not shown) 26 . We have previously shown that high concentrations of C5a can up- , but neither P32 or P59 were able to upregulate heteromer formation between the C5a receptors ( Fig. 3D ).
P32 and P59 inhibit C5a-induced ERK1/2 activation in HMDM but have no effect on C5a-
induced ERK1/2 activation in CHO-C5aR1 cell line
It is well known that C5a binding to C5aR1 induces rapid and robust ERK1/2 activation; we have recently shown that C5a binding to C5aR2 has no such effect on ERK1/2 activation 16 .
Although C5aR2 has been shown to modulate C5aR1 ERK1/2 activation, this has only been tested to date using C5aR2 antibodies 12, 16 . Therefore, P32, P59 and P48 were tested for their ability to either directly stimulate ERK1/2 activation, or inhibit C5a-induced ERK1/2 activation via C5aR1, in HMDMd and a CHO-C5aR1 cell line ( Fig. 4A , B). Neither P32 nor P59 could induce ERK1/2 activation alone in either cell type, but both could significantly inhibit C5a-induced ERK1/2 activation in HMDMs, with no effect in CHO-C5aR1 cells. P48 had no direct activity, or effect on C5a-induced ERK1/2 activation, in either cell type. To further confirm that P32 and P59 were acting selectively via C5aR2, and not C5aR1, C5a-induced ERK1/2 activation was quantified in the presence of the potent, selective C5aR1 antagonist, PMX53 28 .
PMX53, unlike P32 and P59, was able to almost completely inhibit ERK1/2 activation in both cell types, again further suggesting that P32 and P59 do not exert effects at C5aR1 (Fig. 4A, B and Table I ). These data support the theory that C5aR2 can modulate C5aR1 induced ERK1/2 activation most likely through a β-arrestin dependent mechanism, and demonstrates the C5aR2-functional selectivity of P32 and P59.
P32 and P59 inhibit IL-6 release from HMDM
It is widely established that C5a receptors are important for the control of LPS-stimulated cytokine release from macrophages
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. C5a dose-dependently inhibits the release of the proinflammatory cytokines IL-6 and TNFα, whilst increasing the release of the anti-inflammatory cytokine IL-10 from LPS-stimulated HMDMs 30 . We thus tested the ability of P32, P59 and P48
to directly modulate LPS-induced cytokine release from HMDMs. We found that P32 and P59
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8 significantly inhibited the release of IL-6 ( Fig. 5A ), but had no effect on TNFα and IL-10 from LPS-stimulated HMDMs (Fig. 5C , E), whereas P48 again had no effect on any of the cytokines tested (only IL-6 data shown). Interestingly, both P32 and P59 had a similar maximum level of inhibition of IL-6 to C5a. To further demonstrate that P32 and P59 are acting via C5aR2, LPS stimulated IL-6 release from HMDMs was quantified in the presence of the C5aR1 antagonist, PMX53 (Fig. 5B, D, F) . In the presence of PMX53 the effects of C5a on IL-6, TNFα and IL-10
were completely blocked, whereas the inhibition of IL-6 release by P32 and P59 was unchanged.
This result gives further evidence for the functional selectivity of P32 and P59 for C5aR2.
P32 inhibits C5a-induced neutrophil mobilization in wild-type, but not C5aR2 -/-mice
Finally, we were interested in assessing whether these C5aR2-selective ligands could be used to probe for the role of C5aR2 in vivo. We thus tested the effects of P32 in an acute mouse model of C5a-induced neutrophil mobilization. Systemic administration of C5a induces rapid neutrophil mobilization (neutrophilia) 31 , and C5aR2 is known to affect leukocyte migration and adhesion 12, 32 . In our hands, intravenous injection of C5a (50 µg/kg) induced a rapid 6-fold increase in circulating neutrophils within 30 min (Fig. 6A ). When P32 (3 mg/kg i.v.) was administered immediately prior to C5a, a significant 50% inhibition of neutrophil mobilization was observed (Fig. 6A) . Assuming a mouse blood volume of 1.8 mL for a 25g mouse 33 , our concentration of 3 mg/kg would result in C max blood concentrations of ~50 uM, a dose within the active range of this compound from our in vitro studies. To confirm this effect of P32 in vivo was due to activity at C5aR2, the same experiment was repeated in C5aR2 -/-mice. Notably, the inhibitory effect of P32 was completely attenuated in C5aR2 -/-mice ( Fig. 6B ), demonstrating selectivity of P32 for C5aR2 in vivo at the concentration used.
DISCUSSION
We have utilised a novel computationally-designed library of 61 hexa-, hepta-and octapeptides 21 based on the C-terminal sequence of C5a (C-terminal octapeptide sequence = HKDMQLGR-OH) to discover the first functionally selective agonists for C5aR2 (C5L2/GPR77). 9 Subsequently, we showed that these ligands can recruit β-arrestin 2 via C5aR2, modulate C5a-induced ERK1/2 activation and specifically inhibit IL-6 release from human macrophages.
Discovery of functionally selective C5aR2 ligands
C5aR2 was first thought to be solely a recycling decoy receptor, expressed by cells to remove excess C5a from the extracellular fluid, in order to avoid the detrimental C5aR1-mediated effects of high C5a concentrations 13 . It has now been shown that C5aR2 has additional roles in regulating the release of some cytokines and in a number of inflammatory conditions 14, 17, 29 One of the major impediments to a better understanding of the role of C5aR2 is the dearth of selective ligands 20 .
Previously, it has been shown that C5aR2 can recruit and form a complex with β-arrestins, which can modulate ERK1/2 signalling in macrophages and neutrophils 12, 16, 34 . The simplistic view of β-arrestins as only regulators of GPCR desensitisation/internalisation has been updated in recent years. β-arrestins are now known to have important signalling roles both independent of and in competition with G-protein signalling in addition to their role in GPCR recycling and chemotaxis 35 . For example, β-arrestin 2 has been shown to act as part of a negative feedback loop that regulates the inflammatory response during sepsis 36 . With the C5a receptors, IL-6 and β-arrestin 2 being shown to be key components in the progression of sepsis 17, 19, 36 , the ability to now selectively modulate each of these components should further our understanding of this difficult to treat condition. Sepsis currently accounts for ~350 000 deaths/year with a mortality rate of up to 50% and is responsible for 40% of ICU admissions, costing >$25 billion worldwide annually 37 .
The 61-peptide library used in this study was originally designed for binding at C5aR1, Having previously established a BRET C5aR2 β-arrestin 2 recruitment assay 16 the two hit peptides were tested for the ability to recruit β-arrestin 2 via C5aR2. Both, P32 and P59 were able to recruit β-arrestin 2 with ~37-and 6-fold higher efficacy respectively, than the affinity for C5aR2. Even though the peptides had significantly higher efficacy for β-arrestin 2 recruitment, neither was a full agonist when compared to native C5a. P32 and P59 were also both able to inhibit C5a-induced ERK1/2 activation in HMDMs, but had no effect on C5a- from P32 and P59) that did not show significant activity in the original radioligand displacement screening assay. In order to begin to establish structure-activity relationships (SAR), the ligand displacement K i and/or β-arrestin 2 recruitment EC 50 of these compounds could be determined, along with a set of analogues based on the P32/P59 sequences. There is precedent for converting peptide ligands of complement receptors into potent small-molecules 39 , and peptidomimetic approaches could also be investigated.
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In summary, here we report the discovery of two functionally selective ligands (P32, P59) for C5aR2, which are partial agonists (when compared to C5a) for β-arrestin 2 recruitment. Importantly, our current and previous 21 data demonstrate that P32 and P59 are devoid of activity (either as agonists or antagonists) when screened against C3aR and C5aR1 in a range of assays, and can hence be considered as functionally selective ligands for C5aR2. We acknowledge that the utility of these ligands will be as tool compounds, rather than direct therapeutic candidates, due to their low affinity for C5aR2. Nevertheless these tool ligands provide a good starting point to investigate the biological role of C5aR2. This is verified by our demonstration that P32 could inhibit C5a-induced neutrophil mobilization in mice, in a C5aR2-dependent manner. The discovery of these functionally selective C5aR2 ligands will therefore now allow complement researchers to selectively probe the functional role of C5aR2 in vitro and in vivo. We plan to use these ligands as a medicinal chemistry template for development of higher affinity selective ligands for C5aR2. Indeed, the ability of P32 to inhibit C5a-mediated ERK1/2 activation and selectively inhibit IL-6 secretion from human macrophages, and block
C5a-mediated neutrophil mobilization in vivo, indicates that potent and selective C5aR2
agonists may have therapeutic potential as treatments for inflammatory disease. 
METHODS
Materials
Design of the peptide library
The peptide library consisted of 61 octa-, hepta-and hexapeptides designed around the Cterminal sequence and structure of C5a. A two-stage de novo protein design computational framework was used to construct the peptide library, based on flexible structural templates of C5a from molecular dynamics simulations, as previously described 21 . The full list of sequences of the peptide library is in Halai et al, 2014 21 . The computational framework, its evolution and applications in peptide design are described in 21, 40, 41 Peptide synthesis
All initial peptides were synthesized by GenScript (Piscataway, NJ) with acetylated N-termini at >95% purity. The C-termini of all peptides was unblocked. Purity was confirmed by analytical HPLC. The 61 peptides of the library were dissolved in dimethyl sulfoxide (DMSO) at a stock concentration of 10 mM and stored at -20 o C till needed for assay. Lead peptides were then dissolved in DMSO at a stock concentration of 100 mM. Resyntheses of P32 and P59 were conducted by Mimotopes Pty Ltd (Clayton, Vic, Australia) to >95% purity, confirmed by analytical HPLC and LCMS analysis.
Cell Culture and transfection
HEK293 cells were maintained in DMEM containing 10% FBS, 50 IU mL -1 penicillin, 50 mg . Isolated CD14 + monocytes were differentiated in culture for 7 days with 10 ng ml -1 human M-CSF (Miltenyi Biotec) into HMDMs in the presence of IMDM containing L-glutamine supplemented with 10 % FBS, 50 IU ml -1 penicillin and 50 mg ml -1 streptomycin (Life Technologies) 43 .
C5aR2/C5aR1 membrane preparation
Membranes were prepared from Flp-In CHO-C5aR2 and CHO-C5aR1 cells by a previously described method 44 . Briefly, cells were washed with PBS, pH 7. 
BRET assays for recruitment of β-arrestin 2 to C5a receptors and between C5a receptors
Assays were performed as a ligand-induced BRET experiment similar to previously described 16, 27, 47 . In brief, HEK293 cells were transiently transfected with either C5aR1-Rluc8 and β- 
Measurement of cytokine release from HMDM
Briefly, HMDMs were seeded in 96 well tissue culture plates (Nunc) at 100 000 cells/well and allowed to adhere overnight at 37 °C and 5% CO 2. The next day HMDMs were stimulated with E.coli derived LPS (10 ng ml 
Neutrophil mobilization experimental design
The University of Queensland Animal Ethics Committee approved all mouse experiments.
C57BL/6J wild-type mice or C5L2 -/-mice on a C57BL/6J background were given the vehicle (sterile saline) or C5L2 agonist (P32) (3 mg/kg) intravenously into the femoral vein. Following this injection a further intravenous injection of either vehicle (sterile saline) or recombinant mouse C5a (50 µg/kg) was administered to the opposite femoral vein. After 30 minutes blood samples (collected in 1 mg/mL EDTA and 0.1 mg/mL FUT-175) were collected from the abdominal aorta. Total circulating leukocyte counts were determined from blood smears and total white blood cell counts using a hemocytometer.
Data and statistical analysis
The Graphpad Prism version 6 software was used for all statistical and graphical analysis (Graphpad Software, La Jolla, CA, USA). Sigmoidal curves were fitted to the dose-response curves using non-linear regression. Data from at least three separate experiments are expressed as mean, and error bars represent SEM. Statistical analysis was performed using a one-way ANOVA with Dunnett's or Sidak's correction, for multiple comparisons, differences were considered significant if P < 0.05. ) and C5a (0.1-100 nM), P32, P48 or P59 (0.1-100 µM) with or without C5aR1 antagonist PMX53 (10 µM) present.
Cytokine release quantified by ELISA. CTRL represents non-stimulated HMDM. Data is normalised to LPS response (100%) for each donor. Data (mean ± SEM) are representative of at least five independent HMDM donors performed in triplicate (n = 5-8); *P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by one-way ANOVA followed by Dunnett's post hoc test or Sidak's post hoc test for comparisons +/-PMX53. 
